Krystal Biotech (NASDAQ:KRYS) Stock Gets Price Target Trim from Royal Bank Of Canada

Krystal Biotech (NASDAQ:KRYS) had its price target lowered by Royal Bank Of Canada from $400.00 to $375.00 in a research note issued to investors on Tuesday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

A number of other equities analysts have also recently commented on the company. Zacks Research cut Krystal Biotech from a “hold” rating to a “strong sell” rating in a research note on Friday, October 23rd. The Goldman Sachs Group started coverage on Krystal Biotech in a research note on Thursday, September 24th. They set a “buy” rating and a $441.00 price objective for the company. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. HC Wainwright restated a “buy” rating and issued a $361.00 target price on shares of Krystal Biotech in a report on Thursday, October 15th. Finally, Citigroup reaffirmed a “buy” rating on shares of Krystal Biotech in a research note on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $375.00.

Krystal Biotech Trading Down 3.4%

Shares of NASDAQ:KRYS opened at $300.25 on Tuesday. The stock’s 50-day moving average price is $333.61 and its 200-day moving average price is $308.99. Krystal Biotech has a 12-month low of $192.52 and a 12-month high of $382.54. The stock has a market capitalization of $8.90 billion, a P/E ratio of 42.18 and a beta of 0.56.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. The company had revenue of $127.34 million during the quarter, compared to analyst estimates of $125.77 million. As a group, research analysts predict that Krystal Biotech will post 7.74 EPS for the current year.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino Rossi sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the transaction, the director directly owned 50,000 shares in the company, valued at $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 13.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in Krystal Biotech in the second quarter worth $1,554,113,000. William Blair Investment Management LLC bought a new position in Krystal Biotech during the second quarter valued at $211,909,000. Jupiter Topco LLC bought a new position in Krystal Biotech during the second quarter valued at $95,387,000. Bank of America Corp DE bought a new position in Krystal Biotech during the second quarter valued at $95,308,000. Finally, First Trust Advisors LP increased its holdings in shares of Krystal Biotech by 42.9% in the 1st quarter. First Trust Advisors LP now owns 350,521 shares of the company’s stock worth $90,547,000 after buying an additional 105,245 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.